KJ Muldoon's Cure: The First Personalized CRISPR Treatment Changes Medicine Forever
By Sanna the Weaver • Sat Feb 21 2026 • Health
When KJ Muldoon was born with a rare metabolic disorder called severe CPS1 deficiency, his doctors gave him a grim prognosis: without intervention, most children with his condition do not survive their first year. In 2025, a team at Children's Hospital of Philadelphia and Penn Medicine did something that had never been done before — they designed a CRISPR gene-editing therapy from scratch, tailored specifically to KJ's unique genetic mutation, and administered it to him when he was just six months old. By 2026, KJ is alive, developing normally, and has dramatically reduced his dependence on medication. His case has rewritten what medicine believes is possible. What Made KJ's Case Different Previous CRISPR therapies — including Vertex Pharmaceuticals' Casgevy, approved in 2023 for sickle cell disease and beta thalassemia — were designed for specific mutations shared by large patient populations. They are, in a sense, off-the-shelf genetic medicines. KJ's treatment was something fundamentally different: a one-of-a-kind therapy designed for a mutation that only he (or very few patients) has, using a base editing approach that corrects the specific genetic error in his liver cells without cutting the DNA double strand entirely. The design process, from genetic sequencing to therapeutic design to manufacturing, took approximately six months — extraordinarily fast by the standards of drug development. CRISPR-GPT Accelerates Design The speed of KJ's treatment design was partly enabled by CRISPR-GPT, an AI system developed by Stanford researchers in 2025 that can design CRISPR experiments in months rather than years. CRISPR-GPT analyzes a patient's genetic mutation, searches the scientific literature for relevant editing strategies, predicts off-target effects of candidate guide RNAs, and generates experimental designs for laboratory validation — automating a workflow that previously required months of manual scientific work. The combination of CRISPR precision and AI design acceleration is what made a treatment timeline of six months conceivable. "KJ showed us that personalized genetic medicine is not a distant aspiration. It is a present reality — for those who can access it." — Dr. Kiran Musunuru, Penn Medicine, 2026 The Access Question KJ's story illuminates both the promise and the challenge of personalized genomic medicine. His treatment was designed and manufactured through an academic medical center with access to extraordinary scientific resources, FDA emergency authorization pathways, and philanthropic funding. The cost — estimated at over
million for design, manufacturing, and administration — is not covered by any insurance pathway that currently exists. As CRISPR therapies multiply and AI accelerates their design, the central question becomes not whether these treatments can be made, but who can afford to receive them. The risk is a world in which genomic cures exist for thousands of conditions but are accessible only to those wealthy enough to commission them.